SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining attention as a community-driven project with an active developer who is incentivizing growth through airdrops and social engagement. Participants are focused on building momentum and reaching key market milestones, treating the asset as a high-volatility, weekend-focused speculative play.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ remains a focal point for income-focused investors who are actively debating its performance relative to peers like QQQI and SPYI, especially as the community balances tech-heavy growth potential against the consistency of monthly distributions. Conversations are heavily concentrated on dividend capture strategies and the long-term role of the ETF within retirement portfolios, with many investors debating the tax implications of these distributions in taxable versus tax-advantaged accounts.

APE fuels culture. Backed by the best club in the world and hundreds of thousands of holders worldwide, it’s the token for digital and IRL communities, builders, creators, collectors, gamers, and beyond.  APE is the native gas token of ApeChain and is available across multiple ecosystems including Ethereum, Arbitrum, Solana and HyperLiquid.z  ApeCoin's mission is is to supercharge its ecosystem by supporting high-quality builders &amp; reinforcing 3 core pillars: ApeChain, Bored Ape Yacht Club, and Otherside.

ApeCoin

ApeCoin (APE) is seeing heightened trading volume and speculative momentum as community members discuss a potential breakout, fueled by comparisons to recent meme token rallies and anticipation for renewed altcoin season. Many traders are actively debating its technical support levels and volume trends, with some highlighting recent infrastructure upgrades and ecosystem developments as potential catalysts for further price action.

The Sandbox is a community-driven platform where creators can monetize voxel ASSETS and gaming experiences on the blockchain.  SAND is the utility token used throughout The Sandbox ecosystem as the basis of transactions and interactions. It is an ERC-20 utility token built on the Ethereum blockchain. There is a finite supply of 3,000,000,000 SAND.

The Sandbox

The Sandbox is seeing renewed investor interest as gaming tokens heat up, fueled by a broader crypto market revival and anticipation of a metaverse resurgence. Community members are actively discussing potential price appreciation, drawing parallels to historical bull cycles while focusing on the project's long-standing partnerships and ecosystem development as key indicators for future performance.

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant buzz as the Solana-based project highlights its multi-year tenure and community-driven "joke meta" approach to crypto. Supporters are actively engaging through branded social media challenges, poker nights, and collaborative cross-promotions with other tokens to maintain visibility and momentum.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Equity Premium Income ETF

JPMorgan Equity Premium Income ETF

JPMorgan's JEPI and JEPQ are seeing heavy community interest due to their consistent monthly cash flow and defensive structure, which many investors are using to navigate current market volatility. While some participants discuss recent dividend distribution amounts and the role of covered call overlays in stabilizing portfolios, the community remains divided between those prioritizing long-term income accumulation and those concerned about the impact of market fluctuations on net asset value.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased investor activity driven by high-profile research highlighting its post-quantum cryptographic security. While the community remains divided between long-term holders betting on institutional utility and skeptics focusing on past price performance, the stock continues to trend due to its status as a quantum-resistant layer-1 protocol.

Polygon

Polygon is trending as investors debate whether the network's high transaction volume and adoption in stablecoin payments justify its current market performance or signal a deep undervaluation. The community remains polarized, with some bulls aggressively accumulating, citing the shift to the 'Open Money Stack' and payment-focused infrastructure, while others express frustration over continued price stagnation and concerns about dilution.

Wolfspeed, Inc. is an innovator of wide bandgap semiconductors, focused on silicon carbide and gallium nitride (GaN) materials and devices for power and radiofrequency (RF) applications. Its product families include silicon carbide and GaN materials, power devices and RF devices, and its products are targeted for various applications such as electric vehicles, fast charging, 5G, renewable energy and storage, and aerospace and defense. The company was founded by Calvin H. Carter Jr., John W. Palmour, F. Neal Hunter, Eric Hunter, and John Edmond in 1987 and is headquartered in Durham, NC.

Wolfspeed Inc - Ordinary Shares (New)

Wolfspeed Inc

Wolfspeed is drawing intense trader attention as a post-restructuring 'squeeze play' following a significant IRS tax refund that bolstered its cash position and eased balance sheet concerns. The community remains deeply polarized, with bulls tracking the potential for asymmetric upside as the company pivots toward AI data centers, while bears caution against ongoing dilution risks and the stock's volatile history.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as the company approaches a high-stakes Phase 3 clinical data readout, with market participants closely tracking significant short interest and speculative activity. Community sentiment is deeply divided between excitement over the potential for a transformative gene-editing breakthrough and cautious skepticism regarding the stock's volatility and the impact of the company's recent capital-raising efforts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update PR...

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update PR...

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option Palatin Technologies Announces Closing of Upsized...

Summit Therapeutics Inc. (SMMT) - 1100% jump in weekly message volumeThe biopharma company saw a sharp rise in retail chatter on Stocktwits last week, driven by growing analyst optimism around its cancer drug candidate, ivonescimab — a PD-1/VEGF bispecific antibody.&nbsp;Truist, which has a 'Buy' rating and a $35 price target on the stock, called the upcoming survival data from the HARMONi-2 trial of ivonescimab in non-small cell lung cancer one of the year's most anticipated biotech readouts.According to The Fly, Truist said its in-house biostatistics expert believes the study could exceed expectations and demonstrate statistical significance.&nbsp;In a note from late March, Citi said it had developed a "strong conviction" that HARMONi-2 has a 70% chance of delivering a favorable overall survival outcome by the expected year-end update.Meanwhile, Cantor Fitzgerald highlighted co-CEO and chairman Bob Duggan's early exercise of 4 million stock options at $1.58 — roughly four years before expiration — as "quite unusual" and "quite bullish."Retail sentiment for Summit on Stocktwits flipped to 'extremely bullish' from 'neutral' last week, and the stock's year-to-date gains have reached nearly 30%.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_14_at_7_10_22_AM_png_fc435b051c.webp" alt="Screenshot 2025-04-14 at 7.10.22 AM.png" width="1318" height="316"><figcaption>SMMT retail sentiment weekly shift, as of April 11. | source: Stocktwits</figcaption></figure>Palatin Technologies Inc. (PTN) - 600% jump in weekly message volumeCranbury, New Jersey-based Palatin said Thursday that the NYSE American plans to delist its common stock after the company failed to meet the exchange's minimum stockholders' equity requirement by the April 10 deadline.Palatin said it will appeal the decision by April 25 and expects its shares to continue trading on NYSE American during the appeal process.The biopharma company, which develops drugs targeting the melanocortin receptor system, currently runs clinical trials in obesity, dry eye disease, ulcerative colitis, diabetic nephropathy, and other ocular conditions.On Stocktwits, sentiment for Palatin plunged into 'extremely bearish' territory from 'extremely bullish' last week. The stock has lost over 85% this year.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_14_at_7_10_31_AM_png_723d397ddb.webp" alt="Screenshot 2025-04-14 at 7.10.31 AM.png" width="1318" height="316"><figcaption>PTN retail sentiment weekly shift, as of April 11. | source: Stocktwits</figcaption></figure>Recursion Pharmaceuticals Inc. (RXRX) - 500% jump in weekly message volumeShares of Recursion Pharmaceuticals received a big boost last week after the U.S. health regulator unveiled&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rxrx-stock-jumps-after-hours-as-fda-eyes-ai-drug-testing/chfrEfxRbB6">plans</a> to modernize drug testing methodologies.&nbsp;The FDA said it would begin replacing traditional animal testing for monoclonal antibody therapies and other drugs with more "human-relevant" methods, including artificial intelligence (AI) models.This aligns closely with Nvidia-backed Recursion's business model, which uses AI, machine learning, and automation to accelerate drug discovery.&nbsp;On Stocktwits, sentiment for Recursion climbed into the 'extremely bullish' zone from 'bullish' last week, with the stock's year-to-date losses reducing to about 16%.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_14_at_7_34_11_AM_png_ca5ce8aae3.webp" alt="Screenshot 2025-04-14 at 7.34.11 AM.png" width="1318" height="316"><figcaption>RXRX retail sentiment weekly shift, as of April 11. | source: Stocktwits</figcaption></figure>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX

Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025. 

Equity

This account has been verified as an official PTN representative.

Verified Account

Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Princeton, NJ.

PTN
Palatin Technologies Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PTN News

PTNPalatin Technologies Inc.